AbbVie Inc (ABBV)vsAxsome Therapeutics Inc (AXSM)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
AXSM
Axsome Therapeutics Inc
$207.75
+12.94%
HEALTHCARE · Cap: $9.46B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9479% more annual revenue ($61.16B vs $638.50M). ABBV leads profitability with a 6.9% profit margin vs -28.7%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AXSM
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+51.5%
Fair Value
$383.96
Current Price
$207.75
$176.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 65.0% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Trading at 119.4x book value
ROE of -252.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : AXSM
The strongest argument for AXSM centers on Revenue Growth. Revenue growth of 65.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : AXSM
The primary concerns for AXSM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.96 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while AXSM is a hypergrowth play — different risk/reward profiles.
AXSM carries more volatility with a beta of 0.47 — expect wider price swings.
AXSM is growing revenue faster at 65.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100). AXSM offers better value entry with a 51.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Axsome Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?